Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegvisomant in children with growth hormone excess
NCT03882034Phase 3Completed
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development
- Start
- Oct 2019
- Primary completion
- Sep 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of pegvisomant in gigantism, sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development. Primary endpoints: Percent change of IGF-1 z-score from baseline to 12 months and Safety and tolerability of pegvisomant at 1 year. Started Oct 2019; status: completed.
02
Drugs
pegvisomant
03
Conditions
gigantism
Beyond the preview
Go deeper on NCT03882034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03882034.